Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Next-generation T-cell response platform for autoimmune diseases: Production development and documentation

Reference number
Coordinator NEOGAP Therapeutics AB
Funding from Vinnova SEK 200 000
Project duration May 2026 - December 2026
Status Ongoing
Venture Medtech4Health: Competence Enhancement in SME
Call Medtech4Health: Competence Enhancement in Small Businesses, spring 2026

Purpose and goal

Neogap develops diagnostic test kits for autoimmune and neurodegenerative diseases using an innovative technology that enables detection of autoreactive T cells. The test results provide deeper insight into disease mechanisms and may become an important tool in the development of curative therapies. The first product is designed for Multiple Sclerosis. The aim of the project is to define a production process that results in a high-quality product that meets user expectations.

Expected effects and result

Expected results are documentation, with Standard Operating Procedures, as well as a plan for setting up a pilot line for testing.

Planned approach and implementation

In collaboration with a consultant 1) define relevant process flows 2) create necessary documentation, so called Standard Operating Procedures, linked to said flows 3) set requirements for premises and equipment for production 4) compile the plan for implementation and testing of a robust production process

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 19 May 2026

Reference number 2026-00603